Skip to main content

Advertisement

SpringerLink
Log in

Combination antifungal therapy for the treatment of invasive yeast and mold infections

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Combination antifungal therapy has been an area of great research and clinical interest since antifungals became available decades ago, in part driven by the severe morbidity and mortality associated with invasive fungal infections. Because of the availability of newer antifungal agents including echinocandins and expanded-spectrum triazoles, interest in combination antifungal therapy for invasive mold disease, especially invasive aspergillosis, has grown. This review examines combination antifungal therapy for the treatment of yeast and molds, including current studies evaluating combination antifungal therapy in three clinically important invasive fungal infections: candidiasis, cryptococcosis, and aspergillosis. This article focuses on recent clinical data and potential future clinical directions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Codish SD, Tobias JS, Hannigan M: Combined amphotericin B-flucytosine therapy in aspergillus pneumonia. JAMA 1979, 241:2418–2419.

    Article  PubMed  CAS  Google Scholar 

  2. Bennett JE, Dismukes WE, Duma RJ, et al.: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979, 301:126–131.

    Article  PubMed  CAS  Google Scholar 

  3. Dismukes WE, Cloud G, Gallis HA, et al.: Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987, 317:334–341.

    Article  PubMed  CAS  Google Scholar 

  4. van der Horst C, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997, 337:15–21.

    Article  PubMed  Google Scholar 

  5. Lewis RE, Klepser ME, Pfaller MA: Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis. J Infect Dis Pharmacother 1999, 3:61–84.

    Article  CAS  Google Scholar 

  6. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al.: Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693–715.

    Article  PubMed  CAS  Google Scholar 

  7. Baddley JW, Pappas PG: Combination antifungal therapy: clinical potential. Drugs 2005, 65:1461–1480.

    Article  PubMed  CAS  Google Scholar 

  8. Lewis RE, Kontoyiannis DP: Rationale for combination antifungal therapy. Pharmacotherapy 2001, 21(8 pt 2):149S–164S.

    Article  PubMed  CAS  Google Scholar 

  9. Fridkin SK: The changing face of fungal infections in health care settings. Clin Infect Dis 2005, 41:1455–1460.

    Article  PubMed  Google Scholar 

  10. Lewis RE, Diekema DJ, Messer SA, et al.: Comparison of Etest, checquerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002, 49:345–351.

    Article  PubMed  CAS  Google Scholar 

  11. Ghannoum MA, Fu AY, Ibrahim AS, et al.: In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 1995, 39:2459–2465.

    PubMed  CAS  Google Scholar 

  12. Keele DJ, DeLallo VC, Lewis RE, et al.: Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagn Microbiol Infect Dis 2001, 14:121–126.

    Article  Google Scholar 

  13. Polak A: Synergism of polyene antibiotics with 5-fluorocytosine. Chemotherapy 1978, 24:2–16.

    PubMed  CAS  Google Scholar 

  14. Odds FC: Interactions among amphotericin B, 5-flurocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother 1982, 22:763–770.

    PubMed  CAS  Google Scholar 

  15. Brajtburg J, Kobayashi D, Medoff G, et al.: Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics. J Infect Dis 1982, 146:138–146.

    PubMed  CAS  Google Scholar 

  16. Roling E, Klepser ME, Wasson A, et al.: Antifungal activities of fluconazole and caspofungin (MK0991), and anidulafungin (LY303366) alone and in combination against Candida spp. and Cryptococcus neoformans. Diagn Microbiol Infect Dis 2002, 43:13–17.

    Article  PubMed  CAS  Google Scholar 

  17. Thaler M, Bacher J, O’Leary T, et al.: Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. J Infect Dis 1988, 158:80–88.

    PubMed  CAS  Google Scholar 

  18. Sugar AM, Hitchcock CA, Troke PF, et al.: Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995, 39:598–601.

    PubMed  CAS  Google Scholar 

  19. Marine M, Serena C, Pastor FJ, et al.: Combined antifungal therapy in a murine infection by Candida. J Antimicrob Chemother 2006, 58:1295–1298.

    Article  PubMed  CAS  Google Scholar 

  20. Pappas PG, Rex JH, Sobel JD, et al.: Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161–189.

    Article  PubMed  Google Scholar 

  21. Abele-Horn M, Kopp A, Sternberg U, et al.: A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996, 24:426–432.

    Article  PubMed  CAS  Google Scholar 

  22. Rex JH, Pappas PG, Karchmer AW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221–1228.

    Article  PubMed  CAS  Google Scholar 

  23. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al.: International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005, 24:662–664.

    Article  CAS  Google Scholar 

  24. Matthews RC, Rigg G, Hodgetts S, et al.: Preclinical assessment of the clinical efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother. 2003, 47:2208–2216.

    Article  PubMed  CAS  Google Scholar 

  25. Pachl J, Svoboda P, Jacobs F, et al.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006, 42:1404–1413.

    Article  PubMed  CAS  Google Scholar 

  26. Barchiesi F, Gallo D, Caselli F, et al.: In vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother 1999, 44:65–70.

    Article  PubMed  CAS  Google Scholar 

  27. Barchiesi F, Schimizzi AM, Caselli F, et al.: Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000, 44:2435–2441.

    Article  PubMed  CAS  Google Scholar 

  28. Graybill JR, Williams M, Van Cutsem E, et al.: Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Rev Infect Dis 1980, 2:551–558.

    PubMed  CAS  Google Scholar 

  29. Franzot SP, Casadevall A: Pneumocandin L-743, 872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997, 41:331–336.

    PubMed  CAS  Google Scholar 

  30. Bava AJ, Negroni R: Comparative study of six antifungal treatments in an experimental model of murine cryptococcosis. Eur J Epidemiol 1992, 8:422–426.

    Article  PubMed  CAS  Google Scholar 

  31. Polak, A, Scholer HJ, Wall M: Combination therapy of experimental candidiasis, cryptococcosis, and aspergillosis in mice. Chemotherapy 1982, 28:461–479.

    Article  PubMed  CAS  Google Scholar 

  32. Ding JC, Bauer M, Diamond DM, et al.: Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997, 41:1589–1593.

    PubMed  CAS  Google Scholar 

  33. Larsen RA, Bauer M, Thomas AM, et al.: Amphotericin B combined with fluconazole is better than all other combinations for cryptococcal meningitis [abstract 17]. Presented at the Focus on Fungal Infections 12 Meeting. Phoenix, AR; March 20–22, 2002.

  34. Saag MS, Graybill RJ, Larsen RA, et al.: Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000, 30:710–718.

    Article  PubMed  CAS  Google Scholar 

  35. Larsen RA, Leal ME, Chan LS: Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990, 113:183–187.

    PubMed  CAS  Google Scholar 

  36. Saag MS, Powderly WG, Cloud GA, et al.: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992, 326:83–89.

    Article  PubMed  CAS  Google Scholar 

  37. Saag MS, Cloud GA, Graybill JR, et al.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999, 28:291–296.

    Article  PubMed  CAS  Google Scholar 

  38. Larsen RA, Bozzette SA, Jones BE, et al.: Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994, 19:741–745.

    PubMed  CAS  Google Scholar 

  39. Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination therapies for HIV associated cryptococcal meningitis: a randomized trial. Lancet 2004, 363:1764–1767.

    Article  PubMed  CAS  Google Scholar 

  40. Pappas PG, Larsen RA, Chenkostad P, et al.: Combination amphotericin B plus fluconazole versus amphotericin B alone for treatment of acute cryptococcal meningitis [abstract]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 17–20, 2007.

  41. Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med 2002, 347:408–415.

    Article  PubMed  CAS  Google Scholar 

  42. Walsh TJ, Raad I, Patterson TG, et al.: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2–12.

    Article  PubMed  CAS  Google Scholar 

  43. Maertens J, Raad I, Petrikkos G, et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients reftactory to on intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563–1571.

    Article  PubMed  CAS  Google Scholar 

  44. Denning DW, Marr Ka, Lau WM, et al.: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53:337–349.

    Article  PubMed  Google Scholar 

  45. Denning DW, Hanson LA, Perlman AM, et al.: In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992, 15:21–34.

    Article  PubMed  CAS  Google Scholar 

  46. Meletiadis J, Petraitis V, Petratiene R, et al.: Triazole-polyene antagonism in experimental pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006, 194:1008–1018.

    Article  PubMed  CAS  Google Scholar 

  47. Arikan S, Lozano-Chiu M, Paetznik V, et al.: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46:245–247.

    Article  PubMed  CAS  Google Scholar 

  48. Perea SG, Gonzalez G, Fothergill AW, et al.: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002, 46:3039–3041.

    Article  PubMed  CAS  Google Scholar 

  49. Polak A: Combination therapy with antifungal drugs. Mycoses 1988, 31(Suppl 2):45S–53S.

    Google Scholar 

  50. Clemons KV, Espiritu M, Parmar R, et al.: Comparative efficacies of conventional amphotericin b, liposomal amphotericin b (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against murine cental nervous system aspergillosis. Antimicrob Agents Chemother 2005, 49:4867–4875.

    Article  PubMed  CAS  Google Scholar 

  51. Petraitis V, Petraitiene R, Sarafandi AA, et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. Journal Infect Dis 2003, 187:1834–1843.

    Article  CAS  Google Scholar 

  52. Kirkpatrick WR, Perea S, Coco BJ, et al.: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564–2568.

    Article  PubMed  CAS  Google Scholar 

  53. Petraitis V, Petraitiene R, Legit RJ, et al.: Combination antifungal therapy with FK463 plus amphotericin B in treatment of experimental pulmonary aspergillosis [abstract 2003]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; September 26–29, 1999.

  54. Stevens DA, Kan VL, Judson MA, et al.: Practice guidelines for disease caused by Aspergillus. Clin Infect Dis 2000, 30:696–709.

    Article  PubMed  CAS  Google Scholar 

  55. Aliff TB, Maslak PG, Jurcic JG, et al.: Refractory aspergillus pneumonia in patients with acute leukemia. Cancer 2003, 97:1025–1032.

    Article  PubMed  CAS  Google Scholar 

  56. Kontoyiannis DP, Hachen R, Lewis RE, et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98:292–299.

    Article  PubMed  CAS  Google Scholar 

  57. Marr KA, Boeckth M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797–802.

    Article  PubMed  CAS  Google Scholar 

  58. Singh N, Limaye AP, Forrest G, et al.: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81:320–326.

    Article  PubMed  CAS  Google Scholar 

  59. Steinbach WJ, Stevens DA, Denning DW: Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2002, 37(Suppl 3):188S–224S.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, 229 Tinsley Harrison Tower, Birmingham, AL, 35294-0006, USA

    Peter G. Pappas

Authors
  1. John W. Baddley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter G. Pappas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter G. Pappas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baddley, J.W., Pappas, P.G. Combination antifungal therapy for the treatment of invasive yeast and mold infections. Curr Infect Dis Rep 9, 448–456 (2007). https://doi.org/10.1007/s11908-007-0069-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-007-0069-1

Keywords

Search

Navigation